2025
Assessing the impact of revising MenACWY vaccination schedule for adolescents in the United States: a modelling study
Shoukat A, Wells C, Shin T, Potter-Schwartz L, Galvani A, Moghadas S. Assessing the impact of revising MenACWY vaccination schedule for adolescents in the United States: a modelling study. The Lancet Regional Health - Americas 2025, 44: 101033. PMID: 40046840, PMCID: PMC11880592, DOI: 10.1016/j.lana.2025.101033.Peer-Reviewed Original ResearchInvasive meningococcal diseaseInvasive meningococcal disease casesVaccination scheduleVaccine uptakeAlternative schedulesMenACWY vaccination programCase fatality rateHigh-risk adolescentsVaccine introductionBooster doseIMD casesSerogroup CCompare outcomesMenACWY vaccineAsymptomatic infectionImmunization PracticesMeningococcal diseaseVaccine effectivenessIMD incidenceDoseSerogroups AVaccineStudy periodVaccination programIncrease vaccine uptake
2024
Recurrence patterns and evolution of submicroscopic and asymptomatic Plasmodium vivax infections in malaria-endemic areas of the Peruvian Amazon
Castillo S, Alvarez C, Rosas-Aguirre Á, Acosta C, Corder R, Gómez J, Guzmán M, Speybroeck N, Llanos-Cuentas A, Castro M, Rosanas-Urgell A, Ferreira M, Vinetz J, Gamboa D, Torres K. Recurrence patterns and evolution of submicroscopic and asymptomatic Plasmodium vivax infections in malaria-endemic areas of the Peruvian Amazon. PLOS Neglected Tropical Diseases 2024, 18: e0012566. PMID: 39480785, PMCID: PMC11527163, DOI: 10.1371/journal.pntd.0012566.Peer-Reviewed Original ResearchConceptsRisk of P. vivax infectionPlasmodium vivax malaria transmissionFactors associated with recurrenceVivax malaria transmissionPlasmodium vivax infectionMalaria-endemic areasPopulation-based cohort studyFrequency of recurrenceApplication of molecular diagnostic methodsMalaria recurrenceMalaria infectionMalaria transmissionVivax infectionRecurrence rateMolecular diagnostic methodsRecurrence riskConsequences of prolonged exposureFollow-upCohort studyEndemic settingsRecurrenceAsymptomatic infectionAsymptomatic casesInfectionInitial infectionInfluenza Vaccine Effectiveness Against Illness and Asymptomatic Infection in 2022–2023: A Prospective Cohort Study
White E, Grant L, Mak J, Olsho L, Edwards L, Naleway A, Burgess J, Ellingson K, Tyner H, Gaglani M, Lutrick K, Caban-Martinez A, Newes-Adeyi G, Duque J, Yoon S, Phillips A, Thompson M, Britton A, Flannery B, Fowlkes A. Influenza Vaccine Effectiveness Against Illness and Asymptomatic Infection in 2022–2023: A Prospective Cohort Study. Clinical Infectious Diseases 2024, 80: 893-900. PMID: 39446477, DOI: 10.1093/cid/ciae491.Peer-Reviewed Original ResearchInfluenza virus infectionReverse transcription-polymerase chain reactionVirus infectionVaccine effectivenessIncidence of laboratory-confirmed influenza illnessLaboratory-confirmed influenza virus infectionLaboratory-confirmed influenza illnessInfluenza A Virus InfectionAsymptomatic infectionInfluenza season startsLaboratory-confirmed influenzaInfluenza A subtypesCox proportional hazards regressionProspective cohort studyUnvaccinated participantsProportional hazards regressionTranscription-polymerase chain reactionInfluenza illnessInfluenza testingA subtypeDate of infectionEstimates of vaccine effectivenessInfluenza exposureStudy withdrawalProspective cohortLower Microscopy Sensitivity with Decreasing Malaria Prevalence in the Urban Amazon Region, Brazil, 2018–2021 - Volume 30, Number 9—September 2024 - Emerging Infectious Diseases journal - CDC
Rodrigues P, Johansen I, Ladeia W, Esquivel F, Corder R, Tonini J, Calil P, Fernandes A, Fontoura P, Cavasini C, Vinetz J, Castro M, Ferreira M. Lower Microscopy Sensitivity with Decreasing Malaria Prevalence in the Urban Amazon Region, Brazil, 2018–2021 - Volume 30, Number 9—September 2024 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2024, 30: 1884-1894. PMID: 39174028, PMCID: PMC11346994, DOI: 10.3201/eid3009.240378.Peer-Reviewed Original ResearchConceptsEffectiveness of malaria controlDecreasing malaria prevalenceEpidemiology of malariaPoint-of-care microscopyThreshold of microscopyPlasmodium vivaxMalaria prevalenceMalarial infectionMalaria controlMalaria transmissionP. falciparumMicroscopy sensitivityParasite densityAsymptomatic infectionRoutine surveillanceMalariaPrevalence surveyInfectionPrevalenceParasite genotypesTransmission hotspotsElimination strategiesRural residentsMolecular methodsCDCAbsence of Anti-Babesia microti antibody in commercial intravenous immunoglobulin (IVIG)
Kostka J, Maharjan A, Kumar S, Hackenyos D, Krause P, Dieckhaus K. Absence of Anti-Babesia microti antibody in commercial intravenous immunoglobulin (IVIG). PLOS Neglected Tropical Diseases 2024, 18: e0012035. PMID: 38484010, PMCID: PMC10965045, DOI: 10.1371/journal.pntd.0012035.Peer-Reviewed Original ResearchConceptsIntravenous immunoglobulinB. microti antibodiesBabesiosis patientsSpectrum of disease severityCommercial intravenous immunoglobulinEffective treatment strategiesSevere organ damageHost antibody responseImmunocompromised patientsAdjunctive therapyOrgan damageTreatment strategiesAcute andClinical trialsMicroti antibodiesAsymptomatic infectionAntibody responseTherapeutic benefitTherapeutic effectPatientsDisease severityAntibodiesImmunofluorescence assayProtozoan infectionsCommercial samplesHTLV-1 induces an inflammatory CD4+CD8+ T cell population in HTLV-1–associated myelopathy
Maher A, Aristodemou A, Giang N, Tanaka Y, Bangham C, Taylor G, Dominguez-Villar M. HTLV-1 induces an inflammatory CD4+CD8+ T cell population in HTLV-1–associated myelopathy. JCI Insight 2024, 9: e173738. PMID: 38193535, PMCID: PMC10906466, DOI: 10.1172/jci.insight.173738.Peer-Reviewed Original ResearchConceptsHTLV-1-associated myelopathyDP T cellsT cellsHTLV-1Double-positive T cellsAdult T-cell leukemiaT cell populationsT-cell tropismHTLV-1 infectionHuman T-cell leukemia virus type 1Virus type 1T-cell leukemiaCXCR3 expressionPreferential CD4Asymptomatic infectionCNS pathologyIL-6Asymptomatic carriersInflammatory diseasesCytotoxic phenotypeCell leukemiaCell tropismType 1CD4Cell populations
2023
Chapter 1 Computed tomography manifestations and prognosis of mild COVID-19 cases
Wang M, Fakhri G. Chapter 1 Computed tomography manifestations and prognosis of mild COVID-19 cases. 2023, 1-10. DOI: 10.1016/b978-0-443-18493-2.00001-2.Peer-Reviewed Original ResearchMild COVID-19 casesAsymptomatic patientsImaging findingsComputed tomographyAsymptomatic infectionNegative imaging findingsRespiratory tract specimensPositive nucleic acidCT manifestationsInfected casesComputed tomography manifestationsClinical symptomsMild casesAsymptomatic infected casesPatientsMild typeSARS-CoV-2InfectionSARS-CoV-2 virusClinical signsCommonest typeManifestationsCOVID-19 casesSymptomsPrognosis
2022
Animal models of the immunology and pathogenesis of human babesiosis
Kumar A, Kabra A, Igarashi I, Krause P. Animal models of the immunology and pathogenesis of human babesiosis. Trends In Parasitology 2022, 39: 38-52. PMID: 36470781, DOI: 10.1016/j.pt.2022.11.003.Peer-Reviewed Original ResearchConceptsAnimal modelsHuman babesiosisBabesia infectionImmunological mechanismsModerate diseaseOrgan dysfunctionPathologic responseDisease complicationsAsymptomatic infectionSevere diseaseAnimal studiesInfectionPathological processesDiseaseBabesiosisBabesia speciesAnimalsDomestic animalsComplicationsDysfunctionPathogenesisImmunologyEtiologies of Acute Undifferentiated Febrile Illnesses in and near Iquitos from 1993 to 1999 in the Amazon River Basin of Peru
Watts DM, Russell KL, Wooster MT, Sharp TW, Morrison AC, Kochel TJ, Bautista CT, Block K, Guevara C, Aguilar P, Palermo PM, Calampa C, Porter KR, Hayes CG, Weaver SC, de Rosa AT, Vinetz JM, Shope RE, Gotuzzo E, Guzman H, Tesh RB. Etiologies of Acute Undifferentiated Febrile Illnesses in and near Iquitos from 1993 to 1999 in the Amazon River Basin of Peru. American Journal Of Tropical Medicine And Hygiene 2022, 107: 1114-1128. PMID: 36162442, PMCID: PMC9709010, DOI: 10.4269/ajtmh.22-0259.Peer-Reviewed Original ResearchConceptsFebrile illnessAcute undifferentiated febrile illnessUndifferentiated febrile illnessFebrile patientsAcute leptospirosisFebrile casesAsymptomatic infectionIgG antibodiesHealth burdenHealth clinicsClinical dataBlood samplesMicroscopic agglutinationDengue virusPatientsEncephalitis virusBlood smearsHuman morbidityLeptospira sppMalariaFurther studiesArbovirusesHealth impactsBaseline knowledgeEtiologyEpidemiological characteristics of P. vivax asymptomatic infections in the Peruvian Amazon
Villasis E, Castillo S, Guzman M, Torres J, Gomez J, Garro K, Cordova AM, Reategui C, Abanto C, Vinetz J, Gamboa D, Torres K. Epidemiological characteristics of P. vivax asymptomatic infections in the Peruvian Amazon. Frontiers In Cellular And Infection Microbiology 2022, 12: 901423. PMID: 36118037, PMCID: PMC9471197, DOI: 10.3389/fcimb.2022.901423.Peer-Reviewed Original ResearchConceptsCase-control studyAntimalarial treatmentMalaria symptomsHematological parametersControl individualsCommon malaria symptomsNegative microscopy resultsHistory of comorbiditiesMalaria control measuresClinical immunityMalaria microscopyAsymptomatic infectionMalaria infectionEpidemiological characteristicsChronic infectionMost infectionsMalaria eliminationDay 21Positive qPCR resultsInfected individualsPopulation screeningSYM groupInfectionQPCR resultsLast monthImmunity waning after COVID vaccine booster vs. infection—better than expected
Khoury J, Najjar-Debbiny R, Elemy A, Jabbour A, Haj J, Abu-Sini M, Yasin R, Amin M, Hellou E, Nasrallah N, Saffouri A, Hakim F. Immunity waning after COVID vaccine booster vs. infection—better than expected. Infectious Diseases 2022, 54: 828-831. PMID: 35796285, DOI: 10.1080/23744235.2022.2097304.Peer-Reviewed Original ResearchConceptsBooster doseSecond doseThird doseSecond boosterBNT162b2 mRNA COVID-19 vaccineMRNA COVID-19 vaccineCOVID-19 PCRIgG antibody titresBAU/mLCOVID-19 vaccineEMMS Nazareth HospitalVaccine boosterSuggestive symptomsMean titresNasopharyngeal swabsProspective studyAsymptomatic infectionDoses groupsAntibody titresBooster groupGeneral populationHigh titresDoseTitresDosesInsights into Plasmodium vivax Asymptomatic Malaria Infections and Direct Skin-Feeding Assays to Assess Onward Malaria Transmission in the Amazon.
Moreno M, Torres K, Tong C, García Castillo SS, Carrasco-Escobar G, Guedez G, Torres L, Herrera-Varela M, Guerra L, Guzman-Guzman M, Wong D, Ramirez R, Llanos-Cuentas A, Conn JE, Gamboa D, Vinetz JM. Insights into Plasmodium vivax Asymptomatic Malaria Infections and Direct Skin-Feeding Assays to Assess Onward Malaria Transmission in the Amazon. American Journal Of Tropical Medicine And Hygiene 2022, 107: 154-161. PMID: 35895359, PMCID: PMC9294676, DOI: 10.4269/ajtmh.21-1217.Peer-Reviewed Original ResearchConceptsDirect skin feeding assaysMalaria infectionP. vivax malaria infectionsAsymptomatic malaria infectionsVivax malaria infectionMosquito feeding assaysDiverse epidemiological settingsCohort studySymptomatic infectionAsymptomatic individualsAsymptomatic infectionSymptomatic participantsParasite carriersPlasmodium vivaxEpidemiological settingsMalaria transmissionPlasmodium gametocytesInfectionMajor mosquito vectorsDisease transmissibilityParasite infectionLongitudinal studyMosquito vectorsInfection intensityInfectivityClinical manifestations of COVID‐19 breakthrough infections: A systematic review and meta‐analysis
Lee C, Woo W, Kim A, Yon D, Lee S, Koyanagi A, Kim M, Tizaoui K, Dragioti E, Radua J, Lee S, Smith L, Shin J. Clinical manifestations of COVID‐19 breakthrough infections: A systematic review and meta‐analysis. Journal Of Medical Virology 2022, 94: 4234-4245. PMID: 35588301, PMCID: PMC9348075, DOI: 10.1002/jmv.27871.Peer-Reviewed Original ResearchConceptsInvasive mechanical ventilationStatistically significant differenceRisk of hospitalizationRisk of infectionCOVID-19 infectionMechanical ventilationMeta-analysisCOVID-19 breakthrough infectionsSignificant differenceRisk of asymptomatic infectionPatient risk factorsSystematic reviewUnvaccinated individualsBetween-study heterogeneityBreakthrough infectionClinical outcomesClinical manifestationsSupplemental oxygenTreatment strategiesOxygen supplementationAsymptomatic infectionWeb of Science databasesProspective analysisRisk factorsInfectionBiannual and Quarterly Comparison Analysis of Agglutinating Antibody Kinetics on a Subcohort of Individuals Exposed to Leptospira interrogans in Salvador, Brazil
Cruz J, Nery N, Sacramento G, Victoriano R, Montenegro A, Santana J, Costa F, Ko A, Reis M, Wunder E. Biannual and Quarterly Comparison Analysis of Agglutinating Antibody Kinetics on a Subcohort of Individuals Exposed to Leptospira interrogans in Salvador, Brazil. Frontiers In Medicine 2022, 9: 862378. PMID: 35492362, PMCID: PMC9048256, DOI: 10.3389/fmed.2022.862378.Peer-Reviewed Original ResearchMicroscopic agglutination testAntibody kineticsEndemic areasReinfection eventsSubcohort of individualsBurden of leptospirosisLife-threatening diseaseProspective cohortClinical manifestationsAsymptomatic infectionHumoral responseRisk factorsImmune responseLeptospirosis infectionAgglutination testPaucity of informationSerological surveyLeptospirosisSample collection timeInfectionLeptospira interrogansSubcohortFurther studiesHigh rateDiseaseSARS CoV-2 seroprevalence and diagnostic accuracy during a COVID-19 outbreak in a major penitentiary complex in Brazil, June to July 2020
Gouvea-Reis F, da Silva D, Borja L, de Oliveira Dias P, Percio J, Peterka C, de Oliveira J, Sodré G, Feres C, Dos Santos W, Souza F, Teixeira A, Cilião-Alves D, Romero G, Noronha E, Croda J, Haddad R, Ramalho W, de Moraes C, de Araújo W. SARS CoV-2 seroprevalence and diagnostic accuracy during a COVID-19 outbreak in a major penitentiary complex in Brazil, June to July 2020. International Journal Of Prison Health 2022, 19: 143-156. PMID: 38899623, DOI: 10.1108/ijph-08-2021-0083.Peer-Reviewed Original ResearchSARS-CoV-2 seroprevalenceOverall infection fatality rateInfection fatality rateChemiluminescence enzyme immunoassaySymptomatic individualsOverall SARS-CoV-2 seroprevalenceSARS-CoV-2 antibodiesDiagnostic accuracyAntibody rapid testLateral flow immunochromatographic assayCOVID-19 outbreakAsymptomatic infectionVaccination strategiesEligible individualsHigh seroprevalenceFatality ratePositive casesSeroprevalenceSerological assaysEnzyme immunoassayRapid testPriority groupsMass testingLFIA testRepresentative sampleRelative contribution of low-density and asymptomatic infections to Plasmodium vivax transmission in the Amazon: pooled analysis of individual participant data from population-based cross-sectional surveys
Ferreira MU, Corder RM, Johansen IC, Kattenberg JH, Moreno M, Rosas-Aguirre A, Ladeia-Andrade S, Conn JE, Llanos-Cuentas A, Gamboa D, Rosanas-Urgell A, Vinetz JM. Relative contribution of low-density and asymptomatic infections to Plasmodium vivax transmission in the Amazon: pooled analysis of individual participant data from population-based cross-sectional surveys. The Lancet Regional Health - Americas 2022, 9: 100169. PMID: 35663000, PMCID: PMC9161731, DOI: 10.1016/j.lana.2021.100169.Peer-Reviewed Original ResearchIndividual participant dataPolymerase chain reactionClinical manifestationsParasite densityMosquito infectionMalaria transmissionPopulation-based cross-sectional surveyParticipant dataMalaria elimination strategiesPopulation-based surveyHigh parasite densityCross-sectional surveyInfected childrenClinical symptomsAsymptomatic infectionUS National InstitutesAsymptomatic carriersParasite carriersInfectious reservoirVivax transmissionInfectionFundação de Amparo à PesquisaChain reactionNational InstituteElimination strategy
2021
Asymptomatic Plasmodium vivax malaria in the Brazilian Amazon: Submicroscopic parasitemic blood infects Nyssorhynchus darlingi
Almeida GG, Costa PAC, da Silva Araujo M, Gomes GR, Carvalho AF, Figueiredo MM, Pereira DB, Tada MS, Medeiros JF, da Silva Soares I, Carvalho LH, Kano FS, de Castro M, Vinetz JM, Golenbock DT, do Valle Antonelli L, Gazzinelli RT. Asymptomatic Plasmodium vivax malaria in the Brazilian Amazon: Submicroscopic parasitemic blood infects Nyssorhynchus darlingi. PLOS Neglected Tropical Diseases 2021, 15: e0009077. PMID: 34714821, PMCID: PMC8555776, DOI: 10.1371/journal.pntd.0009077.Peer-Reviewed Original ResearchConceptsAsymptomatic individualsP. vivaxP. vivax malaria patientsP. vivax infectionVivax malaria patientsPlasmodium vivax malariaLow endemicity areaMalaria patientsSymptomatic patientsAsymptomatic infectionVivax malariaVivax infectionInfectious reservoirLow parasitemiaUninfected controlsEndemic regionsMalaria transmissionInfectivity ratesMalaria parasitesBiochemical parametersParasitemiaBloodPotential rolePatientsInfectionEstimating Vaccine Efficacy Against Transmission via Effect on Viral Load
Kennedy-Shaffer L, Kahn R, Lipsitch M. Estimating Vaccine Efficacy Against Transmission via Effect on Viral Load. Epidemiology 2021, 32: 820-828. PMID: 34469363, PMCID: PMC8478108, DOI: 10.1097/ede.0000000000001415.Peer-Reviewed Original ResearchConceptsViral load measurementsVaccine efficacyViral loadMeasure of vaccine efficacyRandomized Controlled TrialsEstimates of vaccine efficacyVirological testingAsymptomatic infectionVaccine effectivenessSevere diseaseControlled TrialsViral variantsSARS-CoV-2Estimate efficacyEfficacySARS-CoV-2 pandemicVaccineLoad measurementsInfectionVirus transmissionAutoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths
Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, Manry J, Michailidis E, Hoffmann HH, Eto S, Garcia-Prat M, Bizien L, Parra-Martínez A, Yang R, Haljasmägi L, Migaud M, Särekannu K, Maslovskaja J, de Prost N, Tandjaoui-Lambiotte Y, Luyt CE, Amador-Borrero B, Gaudet A, Poissy J, Morel P, Richard P, Cognasse F, Troya J, Trouillet-Assant S, Belot A, Saker K, Garçon P, Rivière JG, Lagier JC, Gentile S, Rosen LB, Shaw E, Morio T, Tanaka J, Dalmau D, Tharaux PL, Sene D, Stepanian A, Megarbane B, Triantafyllia V, Fekkar A, Heath JR, Franco JL, Anaya JM, Solé-Violán J, Imberti L, Biondi A, Bonfanti P, Castagnoli R, Delmonte OM, Zhang Y, Snow AL, Holland SM, Biggs C, Moncada-Vélez M, Arias AA, Lorenzo L, Boucherit S, Coulibaly B, Anglicheau D, Planas AM, Haerynck F, Duvlis S, Nussbaum RL, Ozcelik T, Keles S, Bousfiha AA, Bakkouri J, Ramirez-Santana C, Paul S, Pan-Hammarström Q, Hammarström L, Dupont A, Kurolap A, Metz CN, Aiuti A, Casari G, Lampasona V, Ciceri F, Barreiros LA, Dominguez-Garrido E, Vidigal M, Zatz M, van de Beek D, Sahanic S, Tancevski I, Stepanovskyy Y, Boyarchuk O, Nukui Y, Tsumura M, Vidaur L, Tangye SG, Burrel S, Duffy D, Quintana-Murci L, Klocperk A, Kann NY, Shcherbina A, Lau YL, Leung D, Coulongeat M, Marlet J, Koning R, Reyes LF, Chauvineau-Grenier A, Venet F, Monneret G, Nussenzweig MC, Arrestier R, Boudhabhay I, Baris-Feldman H, Hagin D, Wauters J, Meyts I, Dyer AH, Kennelly SP, Bourke NM, Halwani R, Sharif-Askari NS, Dorgham K, Sallette J, Sedkaoui S, AlKhater S, Rigo-Bonnin R, Morandeira F, Roussel L, Vinh DC, Ostrowski SR, Condino-Neto A, Prando C, Bonradenko A, Spaan AN, Gilardin L, Fellay J, Lyonnet S, Bilguvar K, Lifton RP, Mane S, Hospital J, Covid-19 A, Anderson M, Boisson B, Béziat V, Zhang S, Vandreakos E, Hermine O, Pujol A, Peterson P, Mogensen T, Rowen L, Mond J, Debette S, de Lamballerie X, Duval X, Mentré F, Zins M, Soler-Palacin P, Colobran R, Gorochov G, Solanich X, Susen S, Martinez-Picado J, Raoult D, Vasse M, Gregersen P, Piemonti L, Rodríguez-Gallego C, Notarangelo L, Su H, Kisand K, Okada S, Puel A, Jouanguy E, Rice C, Tiberghien P, Zhang Q, Cobat A, Abel L, Casanova J, Bigio B, Boucherit S, de la Chapelle A, Chen J, Chrabieh M, Coulibaly B, Liu D, Nemirowskaya Y, Cruz I, Materna M, Pelet S, Seeleuthner Y, Thibault C, Liu Z, Abad J, Accordino G, Achille C, Aguilera-Albesa S, Aguiló-Cucurull A, Aiuti A, Özkan E, Darazam I, Albisures J, Aldave J, Ramos M, Khan T, Aliberti A, Nadji S, Alkan G, Alkhater S, Allardet-Servent J, Allende L, Alonso-Arias R, Alshahrani M, Alsina L, Alyanakian M, Borrero B, Amoura Z, Antolí A, Arrestier R, Aubart M, Auguet T, Avramenko I, Aytekin G, Azot A, Bahram S, Bajolle F, Baldanti F, Baldolli A, Ballester M, Feldman H, Barrou B, Barzagh F, Basso S, Bayhan G, Belot A, Bezrodnik L, Bilbao A, Blanchard-Rohner G, Blanco I, Blandinières A, Blázquez-Gamero D, Bleibtreu A, Bloomfield M, Bolivar-Prados M, Bondarenko A, Borghesi A, Borie R, Botdhlo-Nevers E, Bousfiha A, Bousquet A, Boutolleau D, Bouvattier C, Boyarchuk O, Bravais J, Briones M, Brunner M, Bruno R, Bueno M, Bukhari H, Bustamante J, Agra J, Capra R, Carapito R, Carrabba M, Casari G, Casasnovas C, Caseris M, Cassaniti I, Castelle M, Castelli F, de Vera M, Castro M, Catherinot E, Celik J, Ceschi A, Chalumeau M, Charbit B, Cheng M, Clavé P, Clotet B, Codina A, Cohen Y, Colobran R, Comarmond C, Combes A, Comoli P, Corsico A, Coşkuner T, Cvetkovski A, Cyrus C, Dalmau D, Danion F, Darley D, Das V, Dauby N, Dauger S, De Munter P, de Pontual L, Dehban A, Delplancq G, Demoule A, Desguerre I, Di Sabatino A, Diehl J, Dobbelaere S, Domínguez-Garrido E, Dubost C, Ekwall O, Bozdemir Ş, Elnagdy M, Emiroglu M, Endo A, Erdeniz E, Aytekin S, Lasa M, Euvrard R, Fabio G, Faivre L, Falck A, Fartoukh M, Faure M, Arquero M, Ferrer R, Ferreres J, Flores C, Francois B, Fumadó V, Fung K, Fusco F, Gagro A, Solis B, Gaussem P, Gayretli Z, Gil-Herrera J, Gilardin L, Gatineau A, Girona-Alarcón M, Godínez K, Goffard J, Gonzales N, Gonzalez-Granado L, González-Montelongo R, Guerder A, Gülhan B, Gumucio V, Hanitsch L, Gunst J, Gut M, Hadjadj J, Haerynck F, Halwani R, Hammarström L, Hancerli S, Hariyan T, Hatipoglu N, Heppekcan D, Hernandez-Brito E, Ho P, Holanda-Peña M, Horcajada J, Hraiech S, Humbert L, Hung I, Iglesias A, Íñigo-Campos A, Jamme M, Arranz M, Jimeno M, Jordan I, Yüksek S, Kara Y, Karahan A, Karbuz A, Yasar K, Kasapcopur O, Kashimada K, Keles S, Demirkol Y, Kido Y, Kizil C, Kılıç A, Klocperk A, Koutsoukou A, Król Z, Ksouri H, Kuentz P, Kwan A, Kwan Y, Kwok J, Lagier J, Lam D, Lampropoulou V, Lanternier F, Lau Y, Le Bourgeois F, Leo Y, Lopez R, Leung D, Levin M, Levy M, Lévy R, Li Z, Lilleri D, Lima E, Linglart A, López-Collazo E, Lorenzo-Salazar J, Louapre C, Lubetzki C, Lung K, Luyt C, Lye D, Magnone C, Mansouri D, Marchioni E, Marioli C, Marjani M, Marques L, Pereira J, Martín-Nalda A, Pueyo D, Martinez-Picado J, Marzana I, Mata-Martínez C, Mathian A, Matos L, Matthews G, Mayaux J, McLaughlin-Garcia R, Meersseman P, Mège J, Mekontso-Dessap A, Melki I, Meloni F, Meritet J, Merlani P, Akcan Ö, Meyts I, Mezidi M, Migeotte I, Millereux M, Million M, Mirault T, Mircher C, Mirsaeidi M, Mizoguchi Y, Modi B, Mojoli F, Moncomble E, Melián A, Martinez A, Morandeira F, Morange P, Mordacq C, Morelle G, Mouly S, Muñoz-Barrera A, Nafati C, Nagashima S, Nakagama Y, Neven B, Neves J, Ng L, Ng Y, Nielly H, Medina Y, Cuadros E, Ocejo-Vinyals J, Okamoto K, Oualha M, Ouedrani A, Özçelik T, Ozkaya-Parlakay A, Pagani M, Pan-Hammarström Q, Papadaki M, Parizot C, Parola P, Pascreau T, Paul S, Paz-Artal E, Pedraza S, Pellecer N, Pellegrini S, de Diego R, Pérez-Fernández X, Philippe A, Philippot Q, Picod A, de Chambrun M, Piralla A, Planas-Serra L, Ploin D, Poissy J, Poncelet G, Poulakou G, Pouletty M, Pourshahnazari P, Qiu-Chen J, Quentric P, Rambaud T, Raoult D, Raoult V, Rebillat A, Redin C, Resmini L, Ricart P, Richard J, Rigo-Bonnin R, Rivet N, Rivière J, Rocamora-Blanch G, Rodero M, Rodrigo C, Rodriguez L, Rodriguez-Gallego C, Rodriguez-Palmero A, Romero C, Rothenbuhler A, Roux D, Rovina N, Rozenberg F, Ruch Y, Ruiz M, del Prado M, Ruiz-Rodriguez J, Sabater-Riera J, Saks K, Salagianni M, Sanchez O, Sánchez-Montalvá A, Sánchez-Ramón S, Schidlowski L, Schluter A, Schmidt J, Schmidt M, Schuetz C, Schweitzer C, Scolari F, Sediva A, Seijo L, Seminario A, Sene D, Seng P, Senoglu S, Seppänen M, Llovich A, Shahrooei M, Shcherbina A, Siguret V, Siouti E, Smadja D, Smith N, Sobh A, Solanich X, Solé-Violán J, Soler C, Soler-Palacín P, Sözeri B, Stella G, Stepanovskiy Y, Stoclin A, Taccone F, Tandjaoui-Lambiotte Y, Taupin J, Tavernier S, Tello L, Terrier B, Thiery G, Thorball C, THORN K, Thumerelle C, Tipu I, Tolstrup M, Tomasoni G, Toubiana J, Alvarez J, Triantafyllia V, Trouillet-Assant S, Troya J, Tsang O, Tserel L, Tso E, Tucci A, Öz Ş, Ursini M, Utsumi T, Uzunhan Y, Vabres P, Valencia-Ramos J, Van Den Rym A, Vandernoot I, Velez-Santamaria V, Veliz S, Vidigal M, Viel S, Vilain C, Vilaire-Meunier M, Villar-García J, Vincent A, Vogt G, Voiriot G, Volokha A, Vuotto F, Wauters E, Wauters J, Wu A, Wu T, Yahşi A, Yesilbas O, Yildiz M, Young B, Yükselmiş U, Zatz M, Zecca M, Zuccaro V, Jens V, Lambrecht B, Eva V, Cédric B, Levi H, Eric H, Bauters F, De Clercq J, Cathérine H, Hans S, Leslie N, Florkin B, Boulanger C, Vanderlinden D, Foti G, Bellani G, Citerio G, Contro E, Pesci A, Valsecchi M, Cazzaniga M, Danielson J, Dobbs K, Kashyap A, Ding L, Dalgard C, Sottini A, Quaresima V, Quiros-Roldan E, Rossi C, Bettini L, D’Angio’ M, Beretta I, Montagna D, Licari A, Marseglia G, Batten I, Reddy C, McElheron M, Noonan C, Connolly E, Fallon A, Storgaard M, Jørgensen S, Tolstrup M, Erikstrup C, Pedersen O, Sørensen E, Mikkelsen S, Dinh K, Larsen M, Paulsen I, Von Stemann J, Hansen M, Ostrowski S, Townsend L, Cheallaigh C, Bergin C, Martin-Loeches I, Dunne J, Conlon N, Bourke N, O'Farrelly C, Abel L, Allavena C, Andrejak C, Angoulvant F, Azoulay C, Bachelet D, Bartoli M, Basmaci R, Behilill S, Beluze M, Benech N, Benkerrou D, Bhavsar K, Bitker L, Bouadma L, Bouscambert-Duchamp M, Paz P, Cervantes-Gonzalez M, Chair A, Chirouze C, Coelho A, Cordel H, Couffignal C, Couffin-Cadiergues S, d’Ortenzio E, De Montmollin E, Debard A, Debray M, Deplanque D, Descamps D, Desvallée M, Diallo A, Diehl J, Diouf A, Dorival C, Dubos F, Duval X, Eloy P, Enouf V, Epaulard O, Esperou H, Esposito-Farese M, Etienne M, Garot D, Gault N, Gaymard A, Ghosn J, Gigante T, Gilg M, Goehringer F, Guedj J, Hoctin A, Hoffmann I, Houas I, Hulot J, Jaafoura S, Kafif O, Kaguelidou F, Kali S, Kerroumi Y, Khalil A, Khan C, Kimmoun A, Laine F, Laouénan C, Laribi S, Le M, Le Bris C, Le Gac S, Le Hingrat Q, Le Mestre S, Le Nagard H, Lemaignen A, Lemee V, Lescure F, Letrou S, Levy Y, Lina B, Lingas G, Lucet J, Machado M, Malvy D, Mambert M, Manuel A, Mentré F, Meziane A, Mouquet H, Mullaert J, Neant N, Nguyen D, Noret M, Papadopoulos A, Paul C, Peiffer-Smadja N, Peigne V, Petrov-Sanchez V, Peytavin G, Pham H, Picone O, Piquard V, Poissy J, Puéchal O, Rosa-Calatrava M, Rossignol B, Rossignol P, Roy C, Schneider M, Su R, Tardivon C, Tellier M, Téoulé F, Terrier O, Timsit J, Tual C, Tubiana S, Van Der Werf S, Vanel N, Veislinger A, Visseaux B, Wiedemann A, Yazdanpanah Y, Annereau J, Briseño-Roa L, Gribouval O, Pelet A, Abel L, Alcover A, Aschard H, Bousso P, Bourke N, Brodin P, Bruhns P, Cerf-Bensussan N, Cumano A, D’Enfert C, Deriano L, Dillies M, Di Santo J, Dromer F, Eberl G, Enninga J, Fellay J, Gomperts-Boneca I, Hasan M, Hedestam G, Hercberg S, Ingersoll M, Lantz O, Kenny R, Ménager M, Michel F, Mouquet H, O'Farrelly C, Patin E, Pellegrini S, Rausell A, Rieux-Laucat F, Rogge L, Fontes M, Sakuntabhai A, Schwartz O, Schwikowski B, Shorte S, Tangy F, Toubert A, Touvier M, Ungeheuer M, Zimmer C, Albert M, Duffy D, Quintana-Murci L, Alavoine L, Behillil S, Burdet C, Charpentier C, Dechanet A, Descamps D, Duval X, Ecobichon J, Enouf V, Frezouls W, Houhou N, Kafif O, Lehacaut J, Letrou S, Lina B, Lucet J, Manchon P, Nouroudine M, Piquard V, Quintin C, Thy M, Tubiana S, van der Werf S, Vignali V, Visseaux B, Yazdanpanah Y, Chahine A, Waucquier N, Migaud M, Deplanque D, Djossou F, Mergeay-Fabre M, Lucarelli A, Demar M, Bruneau L, Gérardin P, Maillot A, Payet C, Laviolle B, Laine F, Paris C, Desille-Dugast M, Fouchard J, Malvy D, Nguyen D, Pistone T, Perreau P, Gissot V, Le Goas C, Montagne S, Richard L, Chirouze C, Bouiller K, Desmarets M, Meunier A, Lefévre B, Jeulin H, Legrand K, Lomazzi S, Tardy B, Gagneux-Brunon A, Bertholon F, Botelho-Nevers E, Kouakam C, Leturque N, Roufai L, Amat K, Couffin-Cadiergues S, Espérou H, Hendou S, van Agtmael M, Algera A, Appelman B, van Baarle F, Bax D, Beudel M, Bogaard H, Bomers M, Bonta P, Bos L, Botta M, de Brabander J, de Bree G, de Bruin S, Buis D, Bugiani M, Bulle E, Chouchane O, Cloherty A, Dijkstra M, Dongelmans D, Dujardin R, Elbers P, Fleuren L, Geijtenbeek S, Girbes A, Goorhuis B, Grobusch M, Hafkamp F, Hagens L, Hamann J, Harris V, Hemke R, Hermans S, Heunks L, Hollmann M, Horn J, Hovius J, de Jong M, Koning R, Lim E, van Mourik N, Nellen J, Nossent E, Paulus F, Peters E, Pina-Fuentes D, van der Poll T, Preckel B, Prins J, Raasveld J, Reijnders T, de Rotte M, Schinkel M, Schultz M, Schrauwen F, Schuurmans A, Schuurmans J, Sigaloff K, Slim M, Smeele P, Smit M, Stijnis C, Stilma W, Teunissen C, Thoral P, Tsonas A, Tuinman P, van der Valk M, Veelo D, Volleman C, de Vries H, Vught L, van Vugt M, Wouters D, Zwinderman A, Brouwer M, Wiersinga W, Vlaar A, van de Beek D, Abel L, Aiuti A, Al-Muhsen S, Al-Mulla F, Anderson M, Andreakos E, Arias A, Feldman H, Belot A, Biggs C, Bogunovic D, Bolze A, Bondarenko A, Bousfiha A, Brodin P, Bryceson Y, Bustamante C, Butte M, Casari G, Chakravorty S, Christodoulou J, Condino-Neto A, Constantinescu S, Cooper M, Dalgard C, Desai M, Drolet B, Baghdadi J, Espinosa-Padilla S, Fellay J, Flores C, Franco J, Froidure A, Gregersen P, Haerynck F, Hagin D, Halwani R, Hammarström L, Heath J, Henrickson S, Hsieh E, Husebye E, Imai K, Itan Y, Jarvis E, Karamitros T, Kisand K, Ku C, Lau Y, Ling Y, Lucas C, Maniatis T, Mansouri D, Maródi L, Meyts I, Milner J, Mironska K, Mogensen T, Morio T, Ng L, Notarangelo L, Novelli A, Novelli G, O'Farrelly C, Okada S, Ozcelik T, Pan-Hammarström Q, de Diego R, Planas A, Prando C, Pujol A, Quintana-Murci L, Renia L, Resnick I, Rodríguez-Gallego C, Sancho-Shimizu V, Sediva A, Seppänen M, Shahrooei M, Shcherbina A, Slaby O, Snow A, Soler-Palacín P, Spaan A, Tancevski I, Tangye S, Tayoun A, Ramaswamy S, Turvey S, Uddin K, Uddin M, van de Beek D, Vinh D, von Bernuth H, Zatz M, Zawadzki P, Su H, Casanova J, Nadif R, Goldberg M, Ozguler A, Henny J, Lemonnier S, Coeuret-Pellicer M, Le Got S, Zins M, Tzourio C, Debette S, Dufouil C, Soumaré A, Lachaize M, Fievet N, Flaig A, Martin F, Bonneaudeau B, Cannet D, Gallian P, Jeanne M, Perroquin M, Hamzeh-Cognasse H. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Science Immunology 2021, 6: eabl4340. PMID: 34413139, PMCID: PMC8521484, DOI: 10.1126/sciimmunol.abl4340.Peer-Reviewed Original ResearchConceptsCritical COVID-19Type I IFNDeceased patientsCOVID-19 casesI IFNUninfected individualsCritical COVID-19 pneumoniaFatal COVID-19 casesSARS-CoV-2 infectionCOVID-19Critical COVID-19 casesSevere COVID-19COVID-19 pneumoniaProportion of subjectsConcentration of IFNCOVID-19 deathsUninfected subjectsAsymptomatic infectionGeneral populationPatientsIFNAutoantibodiesHigh concentrationsInfectionSubjectsDiverse functional autoantibodies in patients with COVID-19
Wang EY, Mao T, Klein J, Dai Y, Huck JD, Jaycox JR, Liu F, Zhou T, Israelow B, Wong P, Coppi A, Lucas C, Silva J, Oh JE, Song E, Perotti ES, Zheng NS, Fischer S, Campbell M, Fournier JB, Wyllie AL, Vogels CBF, Ott IM, Kalinich CC, Petrone ME, Watkins AE, Dela Cruz C, Farhadian S, Schulz W, Ma S, Grubaugh N, Ko A, Iwasaki A, Ring A. Diverse functional autoantibodies in patients with COVID-19. Nature 2021, 595: 283-288. PMID: 34010947, DOI: 10.1038/s41586-021-03631-y.Peer-Reviewed Original ResearchConceptsPeripheral immune cell compositionSARS-CoV-2 infectionCOVID-19Effects of autoantibodiesTissue-associated antigensSpecific clinical characteristicsInnate immune activationImmune cell compositionCOVID-19 exhibitCOVID-19 manifestsAnalysis of autoantibodiesSARS-CoV-2Functional autoantibodiesMouse surrogateClinical characteristicsVirological controlClinical outcomesImmune activationMild diseaseAsymptomatic infectionAutoantibody reactivityDisease progressionHealthcare workersHigh prevalenceAutoantibodies
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply